Literature DB >> 18854653

Prognostic significance of alpha V integrin and VEGF in osteosarcoma after chemotherapy.

Yunpeng Huang1, Zhixiong Lin, Jianliang Zhuang, Yifeng Chen, Jianhua Lin.   

Abstract

BACKGROUND: alpha V integrins and vascular endothelial growth factor (VEGF) have been shown to play an important role in osteosarcoma metastasis. However, their expression in osteosarcoma after chemotherapy remains unknown. PATIENTS AND METHODS: Here, using immunohistochemistry, we analyzed the levels of alpha V integrins and VEGF in paraffin sections of 20 patients with untreated osteosarcoma, and 31 patients with adriamycin/cisplatin/ifosfamide-treated osteosarcoma.
RESULTS: Expression of alpha V integrins and VEGF was much higher in osteosarcoma compared with normal bone tissues (p < 0.001) and was reduced dramatically after adriamycin/cisplatin/ifosfamide treatment (p < 0.01). Their expression in osteosarcoma after chemotherapy positively correlated with each other (r = 0.418; p = 0.019, Spearman test). The rank sum test indicated that both positively correlated with osteosarcoma relapse (p < 0.01 and p < 0.05, respectively), Enneking stages (p < 0.05), and invasion of osteosarcoma (p < 0.05), but not with gender, age, tumor necrosis, tumor subtype, or location. VEGF expression was also associated with metastasis incidence (p < 0.05). Multinomial forward conditional logistic regression analysis showed that alpha V integrins might be an independent risk factor of osteosarcoma relapse (odds ratio = 3.96, p = 0.047, 95% confidence interval = (2.12-12.47)).
CONCLUSION: Expression of alpha V integrins and expression of VEGF may be helpful indicators of osteosarcoma diagnosis and predictors of prognosis after chemotherapy, serving as putative targets for osteosarcoma treatment. (c) 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18854653     DOI: 10.1159/000151685

Source DB:  PubMed          Journal:  Onkologie        ISSN: 0378-584X


  8 in total

1.  Effects of vascular endothelial growth factor expression on pathological characteristics and prognosis of osteosarcoma.

Authors:  Gang Han; Yan Wang; Wenzhi Bi; Jinpeng Jia; Wei Wang; Meng Xu
Journal:  Clin Exp Med       Date:  2015-08-29       Impact factor: 3.984

2.  Cyr61 silencing reduces vascularization and dissemination of osteosarcoma tumors.

Authors:  N Habel; M Vilalta; O Bawa; P Opolon; J Blanco; O Fromigué
Journal:  Oncogene       Date:  2014-07-28       Impact factor: 9.867

Review 3.  A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma.

Authors:  Ding Chen; Ye-Jia Zhang; Ke-wei Zhu; Wan-Chun Wang
Journal:  Tumour Biol       Date:  2013-04-16

4.  Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis.

Authors:  Barbara Rossi; Giovanni Schinzari; Giulio Maccauro; Laura Scaramuzzo; Diego Signorelli; Michele A Rosa; Carlo Fabbriciani; Barone Carlo
Journal:  BMC Musculoskelet Disord       Date:  2010-02-16       Impact factor: 2.362

5.  Correlation between the expression of vegf and survival in osteosarcoma.

Authors:  André Mathias Baptista; André Ferrari De França Camargo; Renée Zon Filippi; Cláudia Regina Gomes Cardim Mendes De Oliveira; Raymundo Soares De Azevedo Neto; Olavo Pires De Camargo
Journal:  Acta Ortop Bras       Date:  2014       Impact factor: 0.513

6.  Targeting αvβ3 and αvβ5 integrins inhibits pulmonary metastasis in an intratibial xenograft osteosarcoma mouse model.

Authors:  Ana Gvozdenovic; Aleksandar Boro; Daniela Meier; Beata Bode-Lesniewska; Walter Born; Roman Muff; Bruno Fuchs
Journal:  Oncotarget       Date:  2016-08-23

Review 7.  The role of vascular endothelial growth factor as a prognostic and clinicopathological marker in osteosarcoma: a systematic review and meta-analysis.

Authors:  Chao Zhang; Lin Wang; Chuang Xiong; Runhan Zhao; Hao Liang; Xiaoji Luo
Journal:  J Orthop Surg Res       Date:  2021-12-28       Impact factor: 2.359

8.  Interleukin-6 from Ovarian Mesenchymal Stem Cells Promotes Proliferation, Sphere and Colony Formation and Tumorigenesis of an Ovarian Cancer Cell Line SKOV3.

Authors:  Dah-Ching Ding; Hwan-Wun Liu; Tang-Yuan Chu
Journal:  J Cancer       Date:  2016-08-12       Impact factor: 4.207

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.